These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29880310)

  • 1. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
    Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
    Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
    N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
    JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
    AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
    Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal weight and birth outcomes among women on antiretroviral treatment from conception in a birth surveillance study in Botswana.
    Zash R; Caniglia EC; Diseko M; Mayondi G; Mabuta J; Luckett R; Hofmeyr GJ; Morroni C; Ramogola-Masire D; Williams PL; Zera C; Wylie BJ; Makhema J; Lockman S; Shapiro RL
    J Int AIDS Soc; 2021 Jun; 24(6):e25763. PubMed ID: 34176240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
    Mmasa KN; Powis K; Sun S; Makhema J; Mmalane M; Kgole S; Masasa G; Moyo S; Gerschenson M; Mohammed T; Legbedze J; Abrams EJ; Kurland IJ; Geffner ME; Jao J
    HIV Med; 2021 Sep; 22(8):715-722. PubMed ID: 34003565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
    Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
    Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.
    Caniglia EC; Zash R; Jacobson DL; Diseko M; Mayondi G; Lockman S; Chen JY; Mmalane M; Makhema J; Hernán MA; Shapiro RL
    AIDS; 2018 Jan; 32(1):113-120. PubMed ID: 29112066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
    Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
    N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.
    Zash R; Rough K; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e148-e151. PubMed ID: 29688554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
    Zash R; Souda S; Chen JY; Binda K; Dryden-Peterson S; Lockman S; Mmalane M; Makhema J; Essex M; Shapiro R
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):428-36. PubMed ID: 26379069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.